CSL to challenge GSK
August 1, 2016
WITH the TGA approval of
CSL’s Afluria Quad (inactivated
quadrivalent influenza vaccine)
for prevention of type A and B
influenza, serious competition
enters the quadrivalent vaccine
market in Australia, recently
dominated by GlaxoSmithKline
(GSK) who hold the contract for the
National Immunisation Program
supply.
Afluria Quad is now Australia’s
only locally manufactured,
quadrivalent seasonal influenza
vaccine (QIV) and will also be
exported globally from the Parkville
facility in Melbourne.
CSL’s
vaccine
company
Seqirus,
will rebrand its current trivalent
vaccine Fluvax to the globally used
name Afluria and will have supplies
of Afluria Quad available in time
for the 2017 influenza season, the
company has said.
As the first home-grown quad
influenza vaccine, Afluria Quad is
one of three new chemical entities
registered with the Therapeutic
Goods Administration in July.
The other two were Brenzys
(etanercept) sponsored by Era
Consulting for MSD (PD Fri) for
specific immunological diseases and
Allergan’s Belkyra (deoxycholic acid)
for submental fullness (double chin
appearance).
Visit www.tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 16To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 16
